If tafasitamab/lenalidomide plus R-CHOP (frontMIND) is approved/utilized for frontline treatment, how would you approach second-line therapy in transplant-ineligible patients with relapsed/refractory DLBCL?
How does the prior CD19-directed therapy alter your treatment sequencing strategy?